摘要
近年来,药品注册审评效率问题在"医改"中备受瞩目,审评绩效考核是未来发展的必然趋势。本文通过分析归纳日本的新药审评制度及其绩效考核方案的特点,指出我国新药审评绩效考核方面的可借鉴之处在于加强审评机构的自检工作、突出对新药审评时限的考核以及加强信息公开、提升外部监督作用。
In recent years,the efficiency of drug registration and evaluation has attracted much attention in the healthcare reform.And performance appraisal is an obvious tendency of future development for drug review.This paper analyzed the characteristics of Japanese drug review system and performance appraisal program,pointed out that China's drug review performance appraisal should strengthen the self-inspection work,highlight the evaluation of drug review time,and strengthen information disclosure to improve the external supervision function.
作者
徐怀伏
姚辉屏
席晓宇
XU Huai-fu;YAO Hui-ping;XI Xiao-yu(China Pharmaceutical University, Nanjing 211198, China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第8期849-852,共4页
Chinese Journal of New Drugs
基金
2016年度中国药科大学中央高校基本科研业务费配套项目(2016PTW03)
2016年度中国药科大学国际医药商学院力凡胶囊科研基金资助(CPUSIPB-201610)
2017年度江苏省高校哲学社会科学研究项目(2017SJB0053)
关键词
新药审评
绩效考核
审评时限
new drug review
performance appraisal
review time